Trial Profile
Efficacy and Safety of Valsartan and Aliskiren Combination Therapy in Patients with Diabetic Nephropathy and Hypertension
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Valsartan (Primary) ; Amlodipine
- Indications Diabetic nephropathies; Essential hypertension; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 02 Jul 2013 New trial record